NASDAQ:CASI CASI Pharmaceuticals (CASI) Stock Price, News & Analysis $0.21 0.00 (0.00%) As of 09/25/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsNews and TrendsOptions ChainOwnershipSEC Filings About CASI Pharmaceuticals Stock (NASDAQ:CASI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CASI Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.21▼$0.2150-Day Range$0.21▼$0.2152-Week Range$0.21▼$3.09VolumeN/AAverage Volume482,532 shsMarket Capitalization$2.55 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for cancer and other serious diseases. The company’s activities are concentrated primarily in hematology and oncology, with a geographic focus that includes the United States and China. CASI’s commercial portfolio has included EVOMELA (melphalan for injection), an oncology product used as a conditioning treatment before autologous stem-cell transplantation and as palliative therapy for patients with multiple myeloma. Through its China-based operations, the company has also pursued the development and commercialization of innovative cell therapies, including equecabtagene autoleucel, an investigational or regionally approved CAR-T therapy designed to treat certain relapsed or refractory B-cell malignancies. Founded in the United States, CASI has expanded its operations through partnerships, licensing arrangements and subsidiaries serving the Chinese pharmaceutical market. The company is led by Wei-Wu He, who has served as its chairman and chief executive officer, and continues to focus on advancing oncology products through development, regulatory review and commercialization.AI Generated. May Contain Errors. Read More Receive CASI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CASI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CASI Stock News HeadlinesCASI Pharmaceuticals stock plunges on Nasdaq delisting noticeFebruary 26, 2026 | za.investing.comWhat Drove CASI Pharmaceuticals' 24% Rise After Hours?February 26, 2026 | msn.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.September 28 at 1:00 AM | Porter & Company (Ad)CASI Pharmaceuticals Fails to Renew FOLOTYN Import License in China, Halts SalesJanuary 24, 2026 | theglobeandmail.comCASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated RejectionJanuary 15, 2026 | finanznachrichten.deCASI Pharmaceuticals wins Nasdaq listing extension to February 2026December 23, 2025 | msn.comCASI Pharmaceuticals stock surges after Nasdaq grants listing extensionDecember 23, 2025 | za.investing.comCASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology Annual MeetingDecember 9, 2025 | finanznachrichten.deSee More Headlines CASI Stock Analysis - Frequently Asked Questions How have CASI shares performed this year? CASI Pharmaceuticals' stock was trading at $0.85 on January 1st, 2026. Since then, CASI shares have decreased by 75.6% and is now trading at $0.2075. How were CASI Pharmaceuticals' earnings last quarter? CASI Pharmaceuticals Inc. (NASDAQ:CASI) posted its quarterly earnings data on Friday, November, 14th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by $0.27. The biotechnology company earned $3.08 million during the quarter. When did CASI Pharmaceuticals' stock split? CASI Pharmaceuticals's stock reverse split on the morning of Wednesday, June 1st 2022.The 1-10 reverse split was announced on Wednesday, June 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of CASI Pharmaceuticals? Shares of CASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CASI Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that CASI Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Arista Networks (ANET), Broadcom (AVGO), Novo Nordisk A/S (NVO), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings11/14/2025Today9/28/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (10m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 CASI's financial health is in the Yellow zone, according to TradeSmith. CASI has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CASI CIK1962738 Webwww.casipharmaceuticals.com Phone861065086063Fax301-315-2437Employees180Year Founded1991Profitability EPS (Trailing Twelve Months)($3.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$39.26 million Net Margins-183.93% Pretax Margin-175.56% Return on EquityN/A Return on Assets-131.54% Debt Debt-to-Equity RatioN/A Current Ratio0.30 Quick Ratio0.24 Sales & Book Value Annual Sales$26.85 million Price / Sales0.10 Cash FlowN/A Price / Cash FlowN/A Book Value$0.12 per share Price / Book1.73Miscellaneous Outstanding Shares12,299,000Free Float9,687,000Market Cap$2.55 million OptionableOptionable Beta0.91 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:CASI) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersA Little Known Explorer Sits Near Major Gold DepositsBarrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourm...Wall Street Logic | SponsoredUnder $5, Is This Nasdaq Early to America's Next Defense Boom?Small drones costing hundreds of dollars can now rival tanks and equipment worth millions, a shift Ukraine has...i2i Marketing Group, LLC | SponsoredHOST Just Closed Its Major Merger!Host Digital Inc (NYSE American: HOST) completed its merger with Healthy Choice Wellness Corp on September 17,...Trading Wire | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going t...Decentralized Masters | SponsoredA bill in Congress would require the Treasury to reprice America's gold. Here is what it means for your 401k.The US government still values its gold reserves at $42 an ounce, a price set by Congress back in 1973 and nev...Monetary Gold | SponsoredThe Department of War is on a gold mine's filingsOn May 21, 2026, a federal bank board unanimously approved a nearly $3 billion loan to build a gold mine on Am...Behind the Markets | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CASI Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CASI Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
